Autoimmune Diseases
Welcome,         Profile    Billing    Logout  
 293 Companies   490 Products   490 Products   199 Mechanisms of Action   25 Trials   7787 News 


«12...5253545556575859606162...156157»
  • ||||||||||  New trial:  GPI-II: The GlucoPred Investigation II (clinicaltrials.gov) -  Nov 3, 2015   
    P=N/A,  N=80, Recruiting, 
  • ||||||||||  Trial completion, Trial primary completion date:  GABA-PK: Pharmacokinetics Study of Gamma-aminobutyric Acid (clinicaltrials.gov) -  Nov 2, 2015   
    P1,  N=12, Completed, 
    Recruiting --> Completed | Trial primary completion date: Feb 2014 --> Jul 2014
  • ||||||||||  Lantus (insulin glargine) / Sanofi, insulin peglispro (LY2605541) / Eli Lilly
    Trial primary completion date:  Effects and Response of LY2605541 in Patients With Type 1 Diabetes Mellitus (BIDO) (clinicaltrials.gov) -  Oct 28, 2015   
    P1,  N=32, Recruiting, 
    Recruiting --> Completed | N=96 --> 128 | Trial primary completion date: Jun 2014 --> May 2015 Trial primary completion date: Jul 2015 --> Dec 2015
  • ||||||||||  Trial termination, Trial primary completion date:  Performance of Continuous Glucose Monitoring Systems at Altitude (clinicaltrials.gov) -  Oct 28, 2015   
    P=N/A,  N=10, Terminated, 
    Trial primary completion date: Dec 2014 --> Dec 2016 Suspended --> Terminated | Trial primary completion date: Jul 2012 --> Jul 2017; Suspended awaiting Ministry of Defence ethics approval.
  • ||||||||||  Phase classification, Trial initiation date:  Evaluation of 18 F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell Mass (clinicaltrials.gov) -  Oct 28, 2015   
    P0,  N=9, Active, not recruiting, 
    Suspended --> Terminated | Trial primary completion date: Jul 2012 --> Jul 2017; Suspended awaiting Ministry of Defence ethics approval. Phase classification: P=N/A --> P0 | Initiation date: Nov 2012 --> Jul 2013
  • ||||||||||  BIIB023 / Biogen
    Trial termination, Trial primary completion date:  ATLAS: BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis (clinicaltrials.gov) -  Oct 28, 2015   
    P2,  N=188, Terminated, 
    Trial primary completion date: Mar 2016 --> Dec 2015 Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Dec 2015; Results from a pre-specified criteria did not demonstrate sufficient efficacy to warrant continuation of the study.
  • ||||||||||  BIIB023 / Biogen
    Enrollment change, Trial termination, Trial primary completion date:  BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis (clinicaltrials.gov) -  Oct 28, 2015   
    P2,  N=87, Terminated, 
    Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Dec 2015; Results from a pre-specified criteria did not demonstrate sufficient efficacy to warrant continuation of the study. N=155 --> 87 | Enrolling by invitation --> Terminated | Trial primary completion date: Feb 2019 --> Dec 2015; Results from pre-specified criteria in study NCT01499355 did not demonstrate sufficient efficacy to warrant continuation of the study
  • ||||||||||  Enrollment closed:  Mussels, Inflammation and Rheumatoid Arthritis (MIRA) (clinicaltrials.gov) -  Oct 28, 2015   
    P=N/A,  N=40, Active, not recruiting, 
    N=155 --> 87 | Enrolling by invitation --> Terminated | Trial primary completion date: Feb 2019 --> Dec 2015; Results from pre-specified criteria in study NCT01499355 did not demonstrate sufficient efficacy to warrant continuation of the study Recruiting --> Active, not recruiting
  • ||||||||||  Plegridy (PEG-interferon β-1a) / Biogen
    Trial completion, Enrollment change:  Long-Term Safety and Efficacy Study of Peginterferon Beta-1a (clinicaltrials.gov) -  Oct 28, 2015   
    P3,  N=1077, Completed, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=1500 --> 1077
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Trial completion:  Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy (clinicaltrials.gov) -  Oct 27, 2015   
    P4,  N=54, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Enrollment closed, Trial primary completion date:  MENTOR: MEmbranous Nephropathy Trial Of Rituximab (clinicaltrials.gov) -  Oct 27, 2015   
    P2/3,  N=126, Active, not recruiting, 
    Trial primary completion date: May 2016 --> Nov 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Oct 2016
  • ||||||||||  Betaseron (IFN-β-1b) / Bayer
    Trial completion, Adherence:  China Betaferon Adherence, Coping and Nurse Support Study (clinicaltrials.gov) -  Oct 27, 2015   
    P=N/A,  N=110, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Oct 2016 Active, not recruiting --> Completed
  • ||||||||||  Tavalisse (fostamatinib) / Rigel
    Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date:  Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy (clinicaltrials.gov) -  Oct 23, 2015   
    P2,  N=0, Withdrawn, 
    Enrolling by invitation --> Completed N=25 --> 0 | Initiation date: Jun 2015 --> Sep 2015 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2017 --> Sep 2015
  • ||||||||||  Enrollment closed, Enrollment change, Trial primary completion date:  Closed-loop Control of Postprandial Glucose Levels in Adults With Type 1 Diabetes (clinicaltrials.gov) -  Oct 23, 2015   
    P2,  N=15, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=30 --> 15 | Trial primary completion date: May 2016 --> Oct 2015
  • ||||||||||  Trial primary completion date, Patient reported outcomes:  PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod (clinicaltrials.gov) -  Oct 23, 2015   
    P=N/A,  N=240, Recruiting, 
    Recruiting --> Active, not recruiting | N=30 --> 15 | Trial primary completion date: May 2016 --> Oct 2015 Trial primary completion date: Jan 2016 --> Dec 2016
  • ||||||||||  methylphenidate tablet / Generic mfg.
    Trial primary completion date:  Methylphenidate to Improve Balance and Walking in MS (clinicaltrials.gov) -  Oct 23, 2015   
    P2/3,  N=24, Recruiting, 
    Trial primary completion date: Sep 2015 --> Apr 2016 Trial primary completion date: Jul 2015 --> Jan 2016
  • ||||||||||  Enrollment open, Phase classification:  Mindfulness-based Stress Reduction for Multiple Sclerosis (clinicaltrials.gov) -  Oct 23, 2015   
    P=N/A,  N=60, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Phase classification: P1/2 --> PN/A
  • ||||||||||  Enrollment change, Trial primary completion date:  Role of Neuromuscular Junction Function in Motor Fatigue in Multiple Sclerosis (clinicaltrials.gov) -  Oct 23, 2015   
    P=N/A,  N=40, Recruiting, 
    Not yet recruiting --> Recruiting | Phase classification: P1/2 --> PN/A N=30 --> 40 | Trial primary completion date: Nov 2015 --> Nov 2016
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Enrollment change, Trial termination:  IIT9: Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation (clinicaltrials.gov) -  Oct 23, 2015   
    P4,  N=31, Terminated, 
    N=320 --> 240 | Trial primary completion date: Sep 2015 --> Mar 2016 N=100 --> 31 | Recruiting --> Terminated; Study did not meet required enrollment numbers